JENA, Germany, May 22, 2025 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focused on developing anti-inflammatory treatments by targeting the complement system, announced today its participation in several investor conferences during June and July 2025.

Jefferies Global Healthcare Conference
June 3 – 5, 2025 in New York, NY

InflaRx will deliver an investor presentation on June 4th at 7:35 AM ET and will also hold one-on-one meetings with investors. A registration link for the live stream and replay of the presentation is available .

Oppenheimer Innovators in I&I Summit
June 25, 2025 in New York, NY

InflaRx will participate in a panel discussion titled “Advances in Dermatology: AD and CSU” from 10:45-11:20 AM ET, and will also be available for individual investor meetings.

Leerink Partners Therapeutics Forum: I&I and Metabolism
July 8 – 9, 2025 in Boston, MA
One-on-one investor meetings on June 8.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing its proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a potent inflammatory mediator involved in the progression of various inflammatory diseases. InflaRx’s leading drug candidate, vilobelimab, is a novel, intravenously administered, first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has shown disease-modifying clinical activity and tolerability in multiple clinical trials across different indications. InflaRx is also developing INF904, an orally administered small molecule inhibitor of the C5a receptor. Founded in 2007, InflaRx has offices and subsidiaries in Jena and Munich, Germany, and Ann Arbor, MI, USA. For more information, please visit .

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (collectively, InflaRx).

Contacts:

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. All statements that are not historical facts are forward-looking statements. These statements are often identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” and similar expressions. Forward-looking statements appear in various sections of this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and other factors described in our periodic filings with the SEC under the headings “Risk factors” and “Cautionary statement regarding forward looking statements.” These statements are made only as of the date of this press release and are subject to known and unknown risks, uncertainties, and other significant factors that could cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by the forward-looking statements. Due to these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements. We assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

“`